BioCryst achieves reimbursement for ORLADEYO across major European countries

BioCryst (BCRX) Pharmaceuticals announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO has been approved for the routine prevention of hereditary angioedema attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major European countries, providing HAE patients with access to the first oral, once-daily preventive therapy. This decision in the Netherlands follows the European Commission marketing authorization of ORLADEYO in April 2021. To date, ORLADEYO is commercially available in more than 30 countries.